Skip to main content

Truth or consequences

Dishonesty insurance covers research fraud, US court rules.

Written byPeg Brickley
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

A federal appeals court has ordered an insurer to pay the claim for $1.2 million in "employee dishonesty" damages submitted by a suburban Philadelphia research firm whose employees fabricated some clinical trial records.

Ruling in the case of Scirex Corp. vs. Federal Insurance Co., the 3rd US Court of Appeals said the actions of nurses who falsified data in drug trials were covered by the dishonesty insurance and ordered Federal to pay the costs of re-running the fudged trials.

Representatives of the insurance company declined to comment. The company had argued, in part, that the nurses honestly believed they were complying with trial protocols, so their actions were not really dishonest.

Lying is lying, Chief Judge Edward R. Becker, concluded, regardless of intent.

"After you go through all the analysis, you come back to what your gut sense tells you in the first place," Joseph Roda, attorney for Scirex, told ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Essential Genes Are Dominantly Activated by Single Transcription Factors

Essential Genes Are Dominantly Activated by Single Transcription Factors

EpiCypher Logo
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Miltenyi
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays